Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Articaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Hydrocodone | Articaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Magnesium sulfate | The therapeutic efficacy of Articaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Articaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Articaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Mirtazapine | Articaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Orphenadrine | Articaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Articaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Pramipexole | Articaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Articaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Articaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Articaine. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Articaine is combined with Sodium oxybate. |
| Suvorexant | Articaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Thalidomide | Articaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Articaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Articaine is combined with Prilocaine. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Articaine. |
| Ethanol | Articaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Articaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Articaine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Articaine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Articaine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Articaine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Articaine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Articaine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Articaine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Articaine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Articaine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Articaine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Articaine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Articaine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Articaine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Articaine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Articaine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Articaine is combined with Alaproclate. |
| Dapsone | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Articaine. |
| Technetium Tc-99m tilmanocept | Articaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Articaine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Articaine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Articaine. |
| Promazine | The risk or severity of CNS depression can be increased when Promazine is combined with Articaine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Articaine. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Articaine. |
| Chlorpromazine | The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Articaine. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Articaine. |
| Triflupromazine | The risk or severity of CNS depression can be increased when Triflupromazine is combined with Articaine. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Articaine. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Articaine. |
| Lamotrigine | The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Articaine. |
| Rocuronium | The risk or severity of CNS depression can be increased when Rocuronium is combined with Articaine. |
| Scopolamine | The risk or severity of CNS depression can be increased when Scopolamine is combined with Articaine. |
| Clidinium | The risk or severity of CNS depression can be increased when Clidinium is combined with Articaine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Articaine. |
| Brompheniramine | The risk or severity of CNS depression can be increased when Brompheniramine is combined with Articaine. |
| Flupentixol | The risk or severity of CNS depression can be increased when Flupentixol is combined with Articaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Articaine. |
| Quinidine | The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Articaine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Articaine. |
| Promethazine | The risk or severity of CNS depression can be increased when Promethazine is combined with Articaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Articaine. |
| Doxacurium | The risk or severity of CNS depression can be increased when Doxacurium is combined with Articaine. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Articaine. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Articaine. |
| Quetiapine | The risk or severity of CNS depression can be increased when Quetiapine is combined with Articaine. |
| Mivacurium | The risk or severity of CNS depression can be increased when Mivacurium is combined with Articaine. |
| Aripiprazole | The risk or severity of CNS depression can be increased when Aripiprazole is combined with Articaine. |
| Chlorprothixene | The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Articaine. |
| Metocurine | The risk or severity of CNS depression can be increased when Metocurine is combined with Articaine. |
| Pancuronium | The risk or severity of CNS depression can be increased when Pancuronium is combined with Articaine. |
| Pipecuronium | The risk or severity of CNS depression can be increased when Pipecuronium is combined with Articaine. |
| Rapacuronium | The risk or severity of CNS depression can be increased when Rapacuronium is combined with Articaine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Articaine. |
| Benactyzine | The risk or severity of CNS depression can be increased when Articaine is combined with Benactyzine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Articaine is combined with Dosulepin. |
| Emepronium | The risk or severity of CNS depression can be increased when Articaine is combined with Emepronium. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Articaine. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Articaine. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Articaine. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Articaine. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Articaine. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Articaine. |
| Sulfisoxazole | The risk or severity of methemoglobinemia can be increased when Sulfisoxazole is combined with Articaine. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be decreased when used in combination with Articaine. |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Articaine. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Articaine. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Articaine. |